Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Endogenous incretin levels and risk of first incident cancer: a prospective cohort study

Jujic, Amra LU orcid ; Godina, Christopher LU orcid ; Belting, Mattias LU ; Melander, Olle LU orcid ; Juul Holst, Jens ; Ahlqvist, Emma LU ; Gomez, Maria F LU orcid ; Nilsson, Peter M LU ; Jernström, Helena LU and Magnusson, Martin LU orcid (2023) In Scientific Reports 13. p.1-11
Abstract
Concerns have been raised regarding a potentially increased risk of cancer associated with treatment with glucagon-like peptide-1 (GLP-1) receptor agonists. Here, we explored whether fasting and oral glucose tolerance test post-challenge glucose-dependent insulinotropic peptide (GIP) and GLP-1 levels were associated with incident first cancer. Within the cardiovascular re-examination arm of the population-based Malmö Diet Cancer study (n = 3734), 685 participants with a previous cancer diagnosis were excluded, resulting in 3049 participants (mean age 72.2 ± 5.6 years, 59.5% women), of whom 485 were diagnosed with incident first cancer (median follow-up time 9.9 years). Multivariable Cox-regression and competing risk regression (death as... (More)
Concerns have been raised regarding a potentially increased risk of cancer associated with treatment with glucagon-like peptide-1 (GLP-1) receptor agonists. Here, we explored whether fasting and oral glucose tolerance test post-challenge glucose-dependent insulinotropic peptide (GIP) and GLP-1 levels were associated with incident first cancer. Within the cardiovascular re-examination arm of the population-based Malmö Diet Cancer study (n = 3734), 685 participants with a previous cancer diagnosis were excluded, resulting in 3049 participants (mean age 72.2 ± 5.6 years, 59.5% women), of whom 485 were diagnosed with incident first cancer (median follow-up time 9.9 years). Multivariable Cox-regression and competing risk regression (death as competing risk) were used to explore associations between incretin levels and incident first cancer. Higher levels of fasting GLP-1 (462 incident first cancer cases/2417 controls) showed lower risk of incident first cancer in competing risk regression (sub-hazard ratio 0.90; 95% confidence interval 0.82–0.99; p = 0.022). No association was seen for fasting GIP, post-challenge GIP, or post-challenge GLP-1 and incident first cancer. In this prospective study, none of the fasting and post-challenge levels of GIP and GLP-1 were associated with higher risk of incident first cancer; by contrast, higher levels of fasting GLP-1 were associated with lower risk of incident first cancer. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scientific Reports
volume
13
article number
382
pages
1 - 11
publisher
Nature Publishing Group
external identifiers
  • pmid:36611045
  • scopus:85145864705
ISSN
2045-2322
DOI
10.1038/s41598-023-27509-3
language
English
LU publication?
yes
id
7c3fd1ac-518e-4831-be8f-74d95d4a768c
date added to LUP
2023-01-09 14:11:16
date last changed
2025-10-14 09:33:05
@article{7c3fd1ac-518e-4831-be8f-74d95d4a768c,
  abstract     = {{Concerns have been raised regarding a potentially increased risk of cancer associated with treatment with glucagon-like peptide-1 (GLP-1) receptor agonists. Here, we explored whether fasting and oral glucose tolerance test post-challenge glucose-dependent insulinotropic peptide (GIP) and GLP-1 levels were associated with incident first cancer. Within the cardiovascular re-examination arm of the population-based Malmö Diet Cancer study (n = 3734), 685 participants with a previous cancer diagnosis were excluded, resulting in 3049 participants (mean age 72.2 ± 5.6 years, 59.5% women), of whom 485 were diagnosed with incident first cancer (median follow-up time 9.9 years). Multivariable Cox-regression and competing risk regression (death as competing risk) were used to explore associations between incretin levels and incident first cancer. Higher levels of fasting GLP-1 (462 incident first cancer cases/2417 controls) showed lower risk of incident first cancer in competing risk regression (sub-hazard ratio 0.90; 95% confidence interval 0.82–0.99; p = 0.022). No association was seen for fasting GIP, post-challenge GIP, or post-challenge GLP-1 and incident first cancer. In this prospective study, none of the fasting and post-challenge levels of GIP and GLP-1 were associated with higher risk of incident first cancer; by contrast, higher levels of fasting GLP-1 were associated with lower risk of incident first cancer.}},
  author       = {{Jujic, Amra and Godina, Christopher and Belting, Mattias and Melander, Olle and Juul Holst, Jens and Ahlqvist, Emma and Gomez, Maria F and Nilsson, Peter M and Jernström, Helena and Magnusson, Martin}},
  issn         = {{2045-2322}},
  language     = {{eng}},
  month        = {{01}},
  pages        = {{1--11}},
  publisher    = {{Nature Publishing Group}},
  series       = {{Scientific Reports}},
  title        = {{Endogenous incretin levels and risk of first incident cancer: a prospective cohort study}},
  url          = {{http://dx.doi.org/10.1038/s41598-023-27509-3}},
  doi          = {{10.1038/s41598-023-27509-3}},
  volume       = {{13}},
  year         = {{2023}},
}